On July 28, 2026, the US healthcare sector presented a bright pattern of "dividends and innovation taking off together." On one hand, traditional high-dividend blue chips like Johnson & Johnson (JNJ) and Pfizer (PFE) successively announced increases in quarterly dividends, with dividend yields generally exceeding 3.5%, attracting substantial long-term funds seeking stable returns. On the other hand, the FDA approved three breakthrough therapies for rare diseases and tumors in a row, driving the Biotech Index (XBI) up 2.8% in a single day, with capital beginning to flow back after aggressive sell-offs in the first half of the year. Industry insiders pointed out that with macro interest rates stabilizing and the healthcare sector's valuation at historic lows, tracks with both defensive and growth attributes are becoming a common choice for institutions and retail investors.
Blue-chip dividend hikes: Johnson & Johnson and Pfizer lead dividend increases
According to SGX main board financial news, as of the close on July 28, Dow component Johnson & Johnson announced raising its quarterly dividend from $1.18 per share to $1.22 per share, an increase of about 3.4%, marking the 63rd consecutive year of dividend increases, continuing the "Dividend King" legend. Meanwhile, Pfizer, after divesting some non-core businesses, saw improved cash flow and announced a dividend increase from $0.42 to $0.44 per share, corresponding to an annualized dividend yield of about 4.1%. Additionally, Merck (MRK) and Bristol-Myers Squibb (BMY) also updated their dividend plans this week; the former maintained $0.76 per share unchanged but increased the scale of stock repurchases.
"In an environment of stabilizing interest rates, the dividend payout ratios of pharmaceutical blue chips are generally between 50% and 60%, with high certainty of earnings growth, making them typical high-quality dividend stocks," said Chen Weihao, an analyst at Singapore investment advisory firm AlphaSG. He noted that the current valuation percentile of the US healthcare sector is only below 20% of the past five years. With the Fed's rate cut expectations reigniting, capital is expected to continue flowing into the dividend direction.
FDA approval acceleration: Three innovative drugs approved on the same day, Biotech sentiment warms
The U.S. Food and Drug Administration (FDA) announced three new drug approvals on July 28: a KRAS G12C inhibitor for non-small cell lung cancer (developed by Amgen), an oral small molecule drug for spinal muscular atrophy (under Novartis), and the first tau protein-targeted monoclonal antibody for the early stages of Alzheimer's disease (co-developed by Biogen and Eisai). Following the announcements, the stock prices of the related pharmaceutical companies rose over 5% during intraday trading, with Biogen (BIIB) hitting an 18-month high.
"The FDA's review pace in the second half of 2026 has clearly accelerated, especially for candidate drugs previously designated as breakthrough therapies," analysts at New York biopharmaceutical investment bank Jefferies noted in a report. The three drugs all have blockbuster potential, with combined peak sales estimated at $15 billion. Boosted by this, the SPDR S&P Biotech ETF (XBI), which tracks the innovative drug sector, saw trading volume surge to $4.2 billion on the day, with net capital inflows reaching the second-highest single-day level this year.
High dividends and innovative drugs: Allocation value of two strategies
From an investment perspective, the US healthcare sector can be divided into two major styles: first, dividend blue chips dominated by large pharmaceutical companies, with stable cash flows and continuous dividend growth, suitable for low-risk investors; second, growth-oriented innovative drugs dominated by small and mid-cap Biotech companies, with high volatility but strong explosive potential, suitable for aggressive investors seeking excess returns. The SGX US Healthcare Dividend Focus primarily tracks these two types of targets and offers corresponding ETF fee comparisons and dividend inquiry tools.
- Dividend blue chip representatives: Johnson & Johnson (JNJ), Pfizer (PFE), Merck (MRK), Bristol-Myers Squibb (BMY), with an average dividend yield of 3.8% and a compound dividend growth rate of about 5% over the past five years.
- Innovative Biotech representatives: Biogen (BIIB), Amgen (AMGN), Gilead (GILD), Moderna (MRNA), and a batch of late-stage clinical companies with market caps below $5 billion, such as Sage Therapeutics and Karuna Therapeutics.
Notably, in the first half of 2026, the Biotech sector experienced a correction of over 15% overall due to a tightening financing environment. However, with the FDA approval window opening and increased M&A activity among large pharmaceutical companies (e.g., Novartis acquiring a gene-editing startup for $3.2 billion), institutional views are shifting from cautious to optimistic. JPMorgan's healthcare industry analysts wrote in their latest weekly report: "This is the most attractive moment for Biotech valuations in the past three years. We recommend investors add small positions in innovative targets on top of dividend positions to capture the catalyst-driven rally in the second half of the year."
Cross-border allocation practical guide: How to invest in US healthcare through Singapore platforms
For investors in Singapore and other Asian markets, indirect participation in US healthcare stocks through the SGX main board is a convenient path. Currently, several ETFs tracking US healthcare indices are listed on the Singapore Exchange, such as the iShares U.S. Healthcare ETF (IYH) listed on SGX, with an expense ratio of about 0.42% and support for dual-currency trading in USD and SGD. Additionally, investors can directly open US stock accounts through local brokers (e.g., DBS Vickers, UOB Kay Hian) and enjoy free Dividend Reinvestment Plans (DRIP). The SGX US Healthcare Dividend Focus section has launched real-time dividend calendars and new drug approval tracking features to help ordinary investors keep up with US stock dynamics with zero barriers.
As of press time, the three major US stock indexes were mixed: the Dow rose slightly by 0.2%, the Nasdaq fell 0.5% due to tech stock drags, but the healthcare sector bucked the trend. Against the backdrop of growing rate cut expectations and resilient corporate earnings, dividend- and innovation-driven healthcare stocks are expected to become one of the market's main themes in the second half of the year.
